BioAtla Investor Presentation Deck

Potential market opportunity in metastatic NSCLC >540K ~75-80% ● people in the U.S. living with lung cancer¹ bicatla non-squamous represents majority of NSCLC patients ³ ~200K 2L+ newly diagnosed patients / year (U.S.) - majority advanced / metastatic² despite advances in 1L care, majority of patients progress4 Available Treatment: 1L: Chemo + ICI 50% ORR5 2L+: SOC 14% -23% ORR6: median PFS 4.5 months6 Target population: ~25K ROR2+ addressable 2L+ patients/year in the U.S.7, based on ROR2 positivity rate of ~20% Internal success threshold: 2L+ ORR of 20% (approvability bar based on precedent); 25%+ (commercially relevant) following BA3021 monotherapy small-cell/statistics, ¹https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/resource-library/lung-cancer-fact-sheet 2https://www.cancer.net/cancer-types/lung-cancer-non- ³https://thoracickey.com/carcinomas-of-the-lung-classification-and-genetics/#F1-72, 4Wang F, Wang S and Zhou Q (2020) The Resistance Mechanisms of Lung Cancer Immunotherapy. Front. Oncol. 10:568059. doi: 10.3389/fonc.2020.568059, 5Transl Lung Cancer Res 2021;10(7):3093-3105. 6Cyramza package insert (accessed March 2023) 'Clarivate, Disease Landscape and Forecast: NSCLC (2022). 1L, first line; 2L+, second line or greater; NSCLC, non-small cell lung cancer; ORR, objective response rate (best objective response as confirmed complete response or partial response), SOC, standard of care (docetaxel alone, docetaxel + ramucirumab) BioAtla| Overview 26

View entire presentation